A new trading day began on June 22, 2022, with CymaBay Therapeutics Inc. (NASDAQ: CBAY) stock priced at $2.07, up 16.50% from the previous day of trading. During the day, the shares moved up to $2.4458 and dropped to $2.03 before settling in for the closing price of $2.06. CBAY’s price has ranged from $1.67 to $4.83 over the past 52 weeks.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Meanwhile, its annual earnings per share averaged -71.10%. With a float of $80.92 million, this company’s outstanding shares have now reached $87.80 million.
In an organization with 60 employees, it is important to assess its efficiency.
CymaBay Therapeutics Inc. (CBAY) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CymaBay Therapeutics Inc. is 0.20%, while institutional ownership is 80.50%. The most recent insider transaction that took place on Jun 06, was worth 100,037. In this transaction Chief Executive Officer of this company bought 51,301 shares at a rate of $1.95, taking the stock ownership to the 171,301 shares. Before that another transaction happened on Jan 19, when Company’s Chief Medical Officer bought 20,000 for $3.04, making the entire transaction worth $60,800. This insider now owns 20,000 shares in total.
CymaBay Therapeutics Inc. (CBAY) Latest Financial update
In its latest quarterly report, released on 3/30/2022, the company reported earnings of -$0.32 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a return on equity of -65.30. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -71.10% per share during the next fiscal year.
CymaBay Therapeutics Inc. (NASDAQ: CBAY) Trading Performance Indicators
Here are CymaBay Therapeutics Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 13.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.29 in one year’s time.
Technical Analysis of CymaBay Therapeutics Inc. (CBAY)
Let’s dig in a bit further. During the last 5-days, its volume was 0.78 million. That was better than the volume of 0.52 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 49.75%. Additionally, its Average True Range was 0.17.
During the past 100 days, CymaBay Therapeutics Inc.’s (CBAY) raw stochastic average was set at 39.03%, which indicates a significant decrease from 88.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 112.43% in the past 14 days, which was higher than the 72.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.23, while its 200-day Moving Average is $3.19. However, in the short run, CymaBay Therapeutics Inc.’s stock first resistance to watch stands at $2.55. Second resistance stands at $2.71. The third major resistance level sits at $2.97. If the price goes on to break the first support level at $2.14, it is likely to go to the next support level at $1.88. The third support level lies at $1.72 if the price breaches the second support level.
CymaBay Therapeutics Inc. (NASDAQ: CBAY) Key Stats
With a market capitalization of 196.99 million, the company has a total of 84,678K Shares Outstanding. Currently, annual sales are 0 K while annual income is -90,000 K. The company’s previous quarter sales were 0 K while its latest quarter income was -27,770 K.